RecruitingNot ApplicableNCT07038473

Early Detection of Type 1 Diabetes in First Degree Relatives of Type 1 Diabetes Patients (DETECT T1D GULF)

Islet Autoantibody Early Detection in At-risk Children/Adolescents to Predict Type 1 Diabetes: a Cohort Study in Gulf Countries

Sponsor

Sanofi

Enrollment

3,500 participants

Start Date

Dec 17, 2025

Study Type

INTERVENTIONAL

Conditions

Type 1 Diabetes

Summary

The aim of this research is to identify pre-symptomatic Type 1 Diabetes (T1D) in young children and adolescents who have first degree relatives with T1D. This protocol has been developed to address the growing need for standardized T1D screening, monitoring, and data collection in alignment with international recommendations. The study's estimated duration is 13 months and will consist of two visits: Visit 1 (screening visit) and Visit 2 (confirmatory visit).

Eligibility

Min Age: 18 MonthsMax Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial screens children and teenagers who are close relatives of people with Type 1 diabetes to find early signs of the disease before symptoms appear in Gulf countries. You may be eligible if... - You are a child or teenager between 1.5 and 18 years old - You have a first-degree relative (parent, sibling, or child) with Type 1 diabetes - A parent or legal guardian provides signed informed consent You may NOT be eligible if... - You have already developed Type 1 diabetes - You have any known type of diabetes (Type 1, Type 2, or MODY) - You have previously been treated with insulin Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREInvestigational Procedure

It consists of prospective blood sample collection from children, adolescents and first-degree relatives of T1D probands. Study without any Investigational Medicinal Product (IMP) administration.

Locations(2)

King Abdulaziz Medical City, National Guard Hospital, Jeddah - Site Number: 01

Jeddah, Mecca Region, Saudi Arabia

Sheikh Shakhbout Medical City - Site Number: 06

Abu Dhabi, United Arab Emirates

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07038473

Related Trials

Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes

NCT061445541 location

French Prospective Multicentric Study in Real World

NCT0703994224 locations

CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

NCT0678330928 locations

The Effect of Improved Glycemic Control on the Composition and Function of High-Density Lipoproteins (HDL) in Patients With Type 1 Diabetes

NCT075647521 location

Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D)

NCT072937151 location